Current Report Filing (8-k)
April 15 2020 - 8:06AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of
Report (Date of earliest event reported): April
15, 2020
AYTU BIOSCIENCE, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-38247
|
|
47-0883144
|
(State
or other jurisdictionof incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer Identification No.)
|
373 Inverness Parkway, Suite 206
Englewood, CO 80112
(Address
of principal executive offices, including Zip Code)
Registrant’s
telephone number, including area code: (720) 437-6580
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
|
Written
communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common
Stock, par value $0.0001 per share
|
|
AYTU
|
|
The
NASDAQ Stock Market LLC
|
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this chapter).
Emerging growth
company ☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events
On
April 15, 2020, Aytu BioScience, Inc. (the “Company”) a
specialty pharmaceutical company focused on commercializing novel
products that address significant patient needs today provided an
update on the supply and distribution of the company’s
licensed COVID-19 IgG/IgM Rapid Test. The company has sold or
allocated the initial 100,000 tests to U.S. customers and is
awaiting delivery of the next 500,000 tests.
Additionally,
the company has increased the size of its third purchase order to
one million tests. The company has been informed the order has been
accepted by the manufacturer.
Forward-Looking Statement
This current report on Form 8-K includes forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, or
the Exchange Act. All statements other than statements of
historical facts contained in this presentation, are
forward-looking statements. Forward-looking statements are
generally written in the future tense and/or are preceded by words
such as ''may,'' ''will,'' ''should,'' ''forecast,'' ''could,''
''expect,'' ''suggest,'' ''believe,'' ''estimate,'' ''continue,''
''anticipate,'' ''intend,'' ''plan,'' or similar words, or the
negatives of such terms or other variations on such terms or
comparable terminology. These statements are just predictions and
are subject to risks and uncertainties that could cause the actual
events or results to differ materially. These risks and
uncertainties include, among others: market and other conditions,
the regulatory and commercial risks associated with introducing the
COVID-19 IgG/IgM Rapid Test, shipping delays and their impact on
our ability to introduce the COVID-19 IgG/IgM Rapid Test, our
ability to enforce our exclusive rights to distribute the COVID-19
IgG/IgM Rapid Test in the jurisdictions set forth in the
distribution agreement, the ability of the COVID-19 IgG/IgM Rapid
Test to accurately and reliably test for COVID-19, the manufacture
of the COVID-19 IgG/IgM Rapid Test’s ability to manufacture
such testing kits on a high volume scale, manufacturing problems or
delays related to the COVID-19 IgG/IgM Rapid Test, our ability to
satisfy any labelling conditions or other FDA or other regulatory
conditions to sell the COVID-19 IgG/IgM Rapid Test Kit, the ability
to obtain a sufficient number of COVID-19 IgG/IgM Rapid Test kits
to meet demand if any, the demand or lack thereof for the COVID-19
IgG/IgM Rapid Test Kit, effects of the business combination of Aytu
and the Commercial Portfolio and the recently completed merger
("Merger") with Innovus Pharmaceuticals, including the combined
company's future financial condition, results of operations,
strategy and plans, the ability of the combined company to realize
anticipated synergies in the timeframe expected or at all, changes
in capital markets and the ability of the combined company to
finance operations in the manner expected, the diversion of
management time on Merger-related issues and integration of the
Commercial Portfolio, the ultimate timing, outcome and results of
integrating the operations the Commercial Portfolio and Innovus
with Aytu's existing operations, risks relating to gaining market
acceptance of our products, obtaining or maintaining reimbursement
by third-party payors for our prescription products, the potential
future commercialization of our product candidates, the anticipated
start dates, durations and completion dates, as well as the
potential future results, of our ongoing and future clinical
trials, the anticipated designs of our future clinical trials,
anticipated future regulatory submissions and events, our
anticipated future cash position and future events under our
current and potential future collaboration. We also refer you to
the risks described in ''Risk Factors'' in Part I, Item 1A of the
company's Annual Report on Form 10-K and in the other reports and
documents we file with the Securities and Exchange Commission from
time to time.
Item
9.01 Financial Statements and Exhibits.
(d) The following
exhibit is being filed herewith:
|
|
Press
release announcement dated April 15, 2020
|
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
AYTU BIOSCIENCE, INC.
|
|
|
|
Date:
April 15, 2020
|
By:
|
/s/
Joshua R. Disbrow
|
|
|
Joshua
R. Disbrow
|
|
|
Chief
Executive Officer
|
AYTU BioPharma (NASDAQ:AYTU)
Historical Stock Chart
From Aug 2024 to Sep 2024
AYTU BioPharma (NASDAQ:AYTU)
Historical Stock Chart
From Sep 2023 to Sep 2024